ModifiedColorado Rocky Mountain Health PlansPolicy 2026T0407HH

Intensity‑Modulated Radiation Therapy (IMRT) — Coverage Criteria

Clinical policy governing coverage and medical necessity criteria for IMRT for UnitedHealthcare Commercial and Individual Exchange plans, applicable to individuals aged 19 and older (with special note for those under 19).

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyIntensity‑Modulated Radiation Therapy (IMRT) — Coverage Criteria

Policy CodePolicy 2026T0407HH

Change TypeMaterial revision — added and revised proven indicationsbilling clarification

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionWhen billing multi‑isocenter or active motion‑management IMRT, document the clinical and technical justification to support CPT 77412 (otherwise bill single‑isocenter IMRT under CPT 77407).

SourceLink

POLICY UPDATE CHANGES

Revised list of conditions for which IMRT for Definitive Therapy for the primary site is proven and medically necessary and adjusted specific site criteria.

Added several specific indications as proven and medically necessary: unresectable hepatocellular carcinoma, Hodgkin lymphoma, unresectable intrahepatic cholangiocarcinoma, rectal cancer involving inguinal nodes, limited-stage small cell lung cancer, retroperitoneal/intra-abdominal soft tissue sarcoma, and Stage I-II NSCLC undergoing hypofractionated radiation up to 10 fractions.

Replaced phrasing for breast cancer indication from 'in the [listed] circumstances' to 'when any of the [listed] criteria are met'.

Changed language to consider hippocampal-avoidance whole brain RT of up to 10 fractions as 'considered proven and medically necessary' when criteria are met.

Clarified language indicating IMRT may be considered medically necessary for conditions not defined as proven (including recurrences/metastases) rather than 'may be covered'.

Updated definition of 'Definitive Therapy' and added billing notation clarifying use of CPT 77407 for standard single-isocenter IMRT/VMAT and CPT 77412 for multi-isocenter or single-isocenter with active motion-management (documentation required).

≤10

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

HA‑WBRT fraction limit

~7New proven indications (approx.)

IMRT+PBRTNot covered combination

≥19Age applicability

77407,77412Billing codes noted

Coverage and Medical Necessity Criteria

Definitive Therapy — Proven and Medically Necessary

Covered when ALL of the following are met:

ALL of the following

Intent is definitive therapy directed to the primary site (Definitive Therapy).
Diagnosis is one of the following primary-site conditions: anus/anal canal cancer; breast cancer when any of the following criteria are met: treatment includes left-sided internal mammary nodes OR accelerated partial-breast irradiation (APBI) of up to five fractions; central nervous system tumors (primary or benign) including brain, brainstem, and spinal cord; cervical cancer; endometrial cancer; esophageal cancer; head and neck cancers (including lymphoma and solitary plasmacytomas) when treatment includes pharynx (nasopharynx, oropharynx, hypopharynx), larynx, salivary glands, oral cavity (including tongue), nasal cavity, and paranasal sinuses; hepatocellular carcinoma, unresectable; intrahepatic cholangiocarcinoma, unresectable; Hodgkin lymphoma; mediastinal tumors (e.g., lymphomas, thyroid, thymomas, tracheal cancer); non-small cell lung cancer when any of the following are met: stage I–II undergoing hypofractionated radiation therapy up to 10 fractions, OR stage III undergoing chemoradiation therapy; pancreatic cancer; prostate cancer; rectal cancer when treatment involves inguinal lymph nodes; small cell lung cancer, limited stage; soft tissue sarcoma located in retroperitoneal/intra-abdominal locations; vulvar cancer.
Treatment planning and delivery use IMRT techniques appropriate to tumor and normal‑tissue anatomy (e.g., inverse-planned IMRT, VMAT) with image guidance and motion management as indicated to meet accepted organ-at-risk constraints.
For hippocampal-avoidance whole-brain radiation therapy (HA-WBRT) using IMRT: all the following must be met: brain metastases; ECOG performance status ≤ 2 or Karnofsky performance status ≥ 70; prognosis (expected survival) ≥ 4 months; absence of leptomeningeal disease; and no metastases within the hippocampal‑avoidance region as defined by guideline contouring margins.
Documentation must include disease site, intent (definitive), treatment plan comparison when relevant (see Exceptions/Case-by-Case), and supporting rationale for IMRT over non‑IMRT techniques (e.g., dosimetric comparison demonstrating clinically meaningful normal tissue sparing).

Non‑listed Conditions and Selected Cases — Case‑by‑Case Consideration

Considered medically necessary on a case-by-case basis when ANY of the following apply:

ANY of the following

A dosimetric comparison demonstrates that using a clinically appropriate non‑IMRT technique (e.g., 3D‑CRT) would increase the probability of clinically meaningful normal tissue toxicity, per accepted constraints (RTOG/QUANTEC), and the IMRT plan achieves clinically meaningful reduction in dose to organs at risk versus the non‑IMRT plan.
The same or an immediately adjacent area has been previously irradiated and IMRT is required to sculpt dose to avoid exceeding cumulative tolerance doses of nearby normal tissues.
Complex target geometry, proximity to critical structures, or large/irregular target volumes where established guidelines or multidisciplinary review support IMRT to achieve target coverage while meeting organ‑at‑risk constraints.
Reirradiation scenarios where IMRT is needed to limit dose to previously irradiated normal tissues and enable safe delivery of definitive or salvage therapy.

Procedure Codes, Billing, and Dose Thresholds

Covered/Reference Procedure CodesCPT

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed
77407	Radiation treatment delivery; Level 2, single-isocenter (e.g., 3D or IMRT), photons, including imaging guidance, when performed
77412	Radiation treatment delivery; Level 3, multiple isocenters with photon therapy (e.g., 2D, 3D, or IMRT) or a single-isocenter photon therapy (e.g., 3D or IMRT) with active motion management, or total skin electrons, or mixed-electron/photon field(s), including imaging guidance, when performed
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple, with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex

Procedures and techniques mentionedmixed

No codes listed

No explicit codes in this excerptmixed

No codes listed

FDA device product codesFDA | mixed

MUJ	FDA product code referenced for IMRT devices
IYE	FDA product code referenced for IMRT devices

Applicable CPT Codes for IMRT DeliveryCPT

77407	radiation treatment delivery, intermediate (standard single-isocenter IMRT or VMAT)
77412	radiation treatment delivery, complex (multiple isocenters or single-isocenter delivery with active motion-management; requires documentation to justify level 3)

Biologically effective dose (BED) — IHC dose‑escalation

BED threshold for dose‑escalation in unresectable IHC> 80.5 Gy (BED) — dose associated with improved 3‑year OS and local control in a retrospective cohort

Context of evidenceSingle‑institution retrospective analysis of 79 patients with unresectable intrahepatic cholangiocarcinoma (Tao et al., 2016)

Clinical rationaleBED > 80.5 Gy identified as an ablative threshold when delivered with advanced techniques and image guidance

LimitationsEvidence from retrospective, single‑institution study; individualized planning and OAR sparing required

Expected survival and other eligibility for HA‑WBRT

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required — clinical and technical justification

Prior Authorization and Coding Guidance: Requests for IMRT/VMAT require prior authorization when the indication is not explicitly listed as proven/medically necessary. Case‑by‑case review will evaluate clinical indication, technical necessity, and comparators (e.g., a 3D plan) when an indication is not enumerated in the policy.

When indication is not listed, provide comparative plans showing that a non‑IMRT technique would increase probability of clinically meaningful normal tissue toxicity (RTOG/QUANTEC thresholds).
Document prior radiation to the same or adjacent area and need to sculpt dose to avoid cumulative normal tissue tolerance.
If IMRT is selected for organ‑sparing or complex nodal coverage, include technical justification (anatomy, OAR proximity, target complexity).

Prior Authorization

Indication and Technical Justification — what to submit

Prior authorization should capture the specific clinical indication and technical rationale for IMRT/IGRT selection. Justification must explain why 3D‑CRT cannot meet target coverage and normal tissue goals and include any guideline support for the requested technique.

Background and Scope

Background: External‑beam radiation therapy uses targeted high‑energy beams to treat cancer while sparing normal tissues. IMRT is an advanced delivery technique that modulates beam intensity to conform dose to complex tumor shapes and reduce dose to adjacent organs at risk; image‑guided radiation therapy is commonly used with IMRT to improve targeting accuracy.

Key Definitions

Definitive Therapy — definition and suitability

DefinitionDefinitive Therapy: radiation treatments delivered with curative intent; suitability depends on cancer type and stage

Suitability noteSelection for definitive intent depends on tumor site, stage, patient performance status, and multidisciplinary assessment

Transition from urgent startsUrgent/emergent 2D/3D starts should be transitioned promptly to IMRT when definitive curative therapy is planned (per guideline recommendations)

DP‑IMRT / Dose‑painted IMRT

DefinitionDP‑IMRT (dose‑painted IMRT): an IMRT technique that prescribes different doses to subvolumes (e.g., primary tumor vs elective nodes) within the same treatment course

Clinical exampleUsed in anal cancer (RTOG 0529) to deliver differential doses to primary tumor and involved/elective nodes

Policy Updates and Revision Notes

2026-03-01policy_revisionLatest

Revised list of conditions considered proven and medically necessary for IMRT definitive therapy, including additions (unresectable HCC; Hodgkin lymphoma; unresectable intrahepatic cholangiocarcinoma; rectal cancer involving inguinal nodes; limited-stage SCLC; retroperitoneal/intra-abdominal soft tissue sarcoma; Stage I-II NSCLC with hypofractionation up to 10 fractions) and wording changes (breast indication phrasing, head and neck site list, removal of compensator-based beam modulation language).

2026-03-01coding_update

Added billing clarification: standard single-isocenter IMRT/VMAT should be billed under CPT 77407; CPT 77412 reserved for multi-isocenter or single-isocenter with active motion-management and requires documentation to justify Level 3 delivery.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyIntensity‑Modulated Radiation Therapy (IMRT) — Coverage Criteria

Policy CodePolicy 2026T0407HH

Change TypeMaterial revision — added and revised proven indicationsbilling clarification

Effective DateMar 1, 2026

Next Review DateN/A

SourceLink

On This Page

Situations involving dose‑escalation strategies (e.g., unresectable intrahepatic cholangiocarcinoma) where IMRT is chosen to enable higher biologically effective doses while respecting normal tissue constraints.

When professional society guidelines or tumor‑site specific guidance recommend IMRT for particular clinical scenarios not explicitly listed as proven, and documentation explains why IMRT is expected to reduce toxicity or improve therapeutic ratio for the individual patient.

Expected survival requirement for HA‑WBRT eligibilityExpected survival ≥ 4 months

Additional key eligibility elementsNo metastases within hippocampal‑avoidance region and no leptomeningeal disease; good performance status (ECOG ≤2 or KPS ≥70)

Adjunct pharmacotherapyMemantine is recommended in conjunction with HA‑WBRT

Fractionation noteHA‑WBRT is generally delivered as 30 Gy in 10 fractions when indicated

Intrahepatic cholangiocarcinoma — BED threshold and considerations

BED threshold referenced for IHC dose‑escalation> 80.5 Gy (BED) associated with improved 3‑year OS and local control in unresectable intrahepatic cholangiocarcinoma

Guideline contextASTRO conditionally recommends dose‑escalated IMRT or proton therapy for unresectable IHC, with regimen choice based on tumor location and liver function

Implementation considerationsUse daily CT‑based IGRT and motion management; individualize dosing to liver function and OAR constraints

Describe tumor site, size, relation to organs at risk (OARs), and the anatomic or motion considerations driving advanced technique selection.
Provide simulation data (CT/4D‑CT/PET‑CT), IGRT strategy, and any motion‑management or setup verification planned.
When prior radiation exists, document prior fields and cumulative dose considerations to nearby normal tissues.

Prior Authorization

Prior Authorization for Organ‑Sparing / Complex IMRT

Prior authorization must include organ‑sparing or complex‑IMRT justification when the technique is selected to protect critical structures or to treat complex nodal regions. Include plan comparisons demonstrating meaningful OAR dose reduction.

Submit comparative dosimetry (IMRT vs 3D‑CRT) with dose‑volume histograms for target and critical structures (77301).
Explain specific OAR dose constraints that cannot be met with non‑IMRT techniques and reference QUANTEC/RTOG thresholds.
If treating para‑aortic, inguinal, or other extended nodal regions, describe how IMRT provides coverage while respecting OAR limits.

Prior Authorization

Prior Authorization: Clinical Indications and Image Guidance

Prior authorization for IMRT/IGRT should align with guideline‑supported uses (e.g., anal cancer, PMRT, APBI, cervical, rectal, head and neck postoperative) and indicate planned image guidance and verification frequency. When IMRT is requested for liver, biliary, or thoracic tumors, document individualized dosing strategy and rationale.

For anal cancer, cite ASTRO/NCCN/ESMO recommendations and document daily image guidance when planning IMRT/VMAT.
For PMRT and APBI, document why IMRT/VMAT is preferred and identify IGRT and any DIBH or respiratory control techniques.
For HCC/IHC and biliary tract tumors, document individualized dose selection based on liver function and tumor location; include IGRT use.

Prior Authorization

Justification for Advanced Modalities

Justification for advanced modalities (IMRT/VMAT/advanced IGRT) should be supported by tumor location, proximity to OARs, simulation findings, and relevant guideline recommendations. Requests lacking clinical or technical justification may be denied.

Reference pertinent guidelines (NCCN, ASTRO, ASCO, ESMO) that recommend IMRT for the specific indication.
Provide simulation findings (CT/4D‑CT/PET‑CT) demonstrating that advanced modality is necessary to meet constraints.
State anticipated benefit (e.g., reduction in grade ≥2 GI toxicity, preservation of function) with supporting literature when available.

Prior Authorization

Guideline‑Supported Prior Authorization

Guideline‑supported prior authorization: indicate guideline citations when IMRT/VMAT is the preferred technique (e.g., anal carcinoma, PMRT when 3D‑CRT cannot meet goals, postoperative head & neck, selected rectal and thoracic indications).

Anal cancer: ASTRO/NCCN/ESMO recommend IMRT/VMAT; include regimen and image guidance plans.
PMRT: cite ASTRO/ASCO/SSO guidance recommending IMRT when 3D‑CRT is inadequate and include IGRT plan.
Rectal and thoracic: include conditional recommendations (ASTRO/NCCN) and document why IMRT is needed for node coverage or to spare OARs.

Billing Rule

Billing and Member‑Specific Plan Reference

Billing and Plan Reference: Coverage decisions are subject to the member specific benefit plan. Use CPT 77407 for standard single‑isocenter IMRT/VMAT delivery; use CPT 77412 for multi‑isocenter treatments or single‑isocenter with active motion management. Documentation must justify Level 3 billing when 77412 is reported.

Reference the member's benefit plan and applicable state/federal mandates when confirming coverage.
When billing 77412, document the clinical/technical circumstances that require multiple isocenters or active motion management.
Include relevant planning codes (77301, 77338, 77387) and note that code lists are informational; benefit coverage determined by the member plan.

Denial Risk

IMRT with Proton Therapy — Not Covered

IMRT combined with proton beam radiation therapy (PBRT) in the same plan is considered unproven and not medically necessary. Requests proposing combined IMRT+PBRT delivery should be denied absent high‑quality supportive evidence.

Plans that mix IMRT and PBRT for the same target are unsupported by the literature.
If PBRT is considered, submit PBRT‑specific justification and codes (77520–77525); do not bill IMRT and PBRT together for the same fractions.

Note

Administrative and Step‑Therapy Notes

Administrative Requirements: There are no explicit step‑therapy requirements specified in this section. Prior authorization is required when indicated by the member plan or when the clinical/technical justification is necessary for peer review.

Check the member specific benefit plan for any local administrative triggers or prior authorization processes.
No routine step‑therapy or mandatory trials of 3D‑CRT are specified, but a documented step rationale is expected when transitioning from 3D‑CRT to IMRT.

Prior Authorization

Prior Radiation and Cumulative Dose — required documentation

Prior Radiation and Cumulative Dose Considerations: When prior radiation to the same or adjacent area exists, document prior fields, doses, and cumulative normal tissue tolerance. Re‑irradiation decisions should reflect cumulative late toxicity risk.

Provide prior treatment records, dose distributions, and cumulative dose calculations for nearby OARs.
Explain how IMRT/IGRT will be used to limit overlap and respect cumulative tolerance.

Prior Authorization

IMRT vs Brachytherapy — substitution caution

IMRT versus Brachytherapy: Do not routinely substitute IMRT for brachytherapy when brachytherapy is the guideline‑preferred approach (e.g., intact cervical cancer). Provide justification if IMRT is proposed as an alternative.

For intact cervical disease, document reasons IMRT is being considered instead of brachytherapy and reference NCCN/ASTRO guidance.
If brachytherapy is contraindicated, include clinical rationale and supporting records.

Prior Authorization

Eligibility for Hippocampal‑Avoidance WBRT (HA‑WBRT)

Eligibility for HA‑WBRT: Document criteria when seeking hippocampal‑avoidance whole‑brain radiation therapy plus memantine — patient must have no hippocampal metastases, expected survival ≥ 4 months, and meet performance status criteria.

Include brain imaging confirming absence of lesions within 5 mm of the hippocampus and performance status (ECOG ≤ 2 or KPS ≥ 70).
Specify memantine prescription when HA‑WBRT is requested and note recommended dose/fractionation (e.g., 30 Gy in 10 fractions).

Prior Authorization

Dose Individualization and Image Guidance

Dose Individualization and Image Guidance: For liver, biliary, thoracic, and other high‑risk sites, individualize dose based on organ function and constraints, and document planned IGRT and motion management to support safe delivery.

State the patient's liver function and how dose selection was individualized to avoid radiation‑induced liver disease.
Describe IGRT frequency (daily CBCT or equivalent), motion‑management (4D‑CT, gating, DIBH), and any adaptive planning strategy.

Prior Authorization

High‑Dose CRT Risk — document rationale

High‑Dose Concurrent Chemoradiation Risk: High‑dose (e.g., 74 Gy) concurrent chemoradiation has been associated with worse overall survival and greater toxicity in some trials (e.g., RTOG 0617). Document dose rationale and balance potential risks when high dose regimens are proposed.

If proposing dose escalation above commonly accepted standards, include trial data or rationale and toxicity mitigation plans.
Consider alternative standard‑dose regimens when evidence indicates potential harm.

Documentation Required

Medical Records and Coding Documentation — what reviewers need

Medical Records and Coding Documentation: Medical records required for review include clinical notes, operative and pathology reports, prior radiation dose distributions, simulation images, treatment plans, and justification for chosen technique. Documentation supports coverage determination but does not guarantee payment.

Include tumor site, stage, prior therapies, treatment intents, and rationale for IMRT vs alternatives.
Provide complete planning documentation: 77301 (IMRT plan), DVHs, MLC documentation (77338), IGRT guidance (77387), and delivery codes as applicable.

Documentation Required

Guideline‑Based Documentation — strengthen prior authorization

Guideline‑Based Documentation: When guidelines support the requested technique (e.g., ASTRO, NCCN, ESMO), attach the relevant guideline excerpts or citations and summarize how the patient's presentation meets guideline criteria.

For anal cancer or PMRT, cite the guideline recommendation and describe how planned dose, volumes, and image guidance align.
For rectal, thoracic, head & neck, and other conditional recommendations, note the specific implementation remarks (e.g., daily IGRT, SIB use).

Documentation Required

Technical Rationale and Image Guidance — required evidence

Technical Rationale and Image Guidance Documentation: Demonstrate that 3D‑CRT cannot meet coverage/OAR goals by providing comparative planning and DVH evidence, and specify the IGRT technique to be used during treatment.

Provide 3D‑CRT vs IMRT comparative plans and DVHs highlighting dose reductions to OARs.
State planned image guidance (daily CBCT, orthogonal imaging, surface guidance) and frequency of setup verification.

Documentation Required

Clinical Rationale and IGRT — capture functional goals

Clinical Rationale and IGRT Documentation: For indications where IMRT is chosen to reduce toxicity or preserve function (e.g., head & neck postoperative, pelvic reconstruction, vulvar cancer), document the clinical benefit sought and the IGRT approach to ensure reproducible delivery.

Describe functional preservation goals (speech, swallowing, cosmesis) or organ‑sparing objectives with expected clinical impact.
For vulvar and other anatomies prone to change, document plan for daily setup verification and prompt transition from urgent 2D/3D starts to definitive IMRT.

Documentation Required

Radiation Planning and OAR Sparing — essential plan elements

Radiation Planning and OAR Sparing Documentation: Include tumor site, relationship to OARs, detailed dose constraints, and evidence that IMRT/IGRT is planned to spare organs at risk while achieving target coverage.

Attach target volumes, prescribed dose and fractionation, and explicit OAR constraints used for planning.
Document how IMRT will achieve required constraints when 3D techniques cannot, including any use of SIB or compensators.

Documentation Required

Simulation and Technique — submission checklist

Simulation and Technique Documentation: CT‑based simulation (including 4D‑CT or PET‑CT when indicated), immobilization, motion management, and planned adaptive or image‑guided techniques must be described to justify advanced delivery.

Provide simulation modality and date, contours used for planning, and any respiratory or motion management employed.
If adaptive planning is anticipated, include the trigger criteria and frequency for plan adaptation.

Documentation Required

Clinical Justification Documentation — evidence summary

Clinical Justification Documentation: When asserting superiority of IMRT over alternatives, include summaries of trials or guideline excerpts that support the choice and explain why alternatives are unsuitable for the patient.

Summarize key trial or guideline evidence (e.g., reduced GI toxicity with IMRT in rectal cancer; preferred use in anal cancer and PMRT).
Explain patient‑specific factors (anatomy, prior treatment, comorbidities) that rule out alternatives.

Prior Authorization

Image Guidance and Normal Tissue Protection

Image Guidance and Normal Tissue Protection: Describe plans for image‑guided IMRT to accommodate anatomical changes (e.g., vulvar edema, tumor shrinkage) and preserve normal tissues within tolerance limits; daily verification is often required for changing anatomies.

For anatomies prone to change, document daily CBCT or equivalent verification and contour update strategy.
State how IGRT will be used to protect rectum, bladder, small bowel, femoral heads, heart, and lungs as applicable.

Documentation Required

77412 Documentation Requirement — justify Level 3 billing

CPT 77412 Documentation Requirement: When reporting CPT 77412 (Level 3 delivery), include explicit documentation describing why Level 3 delivery is necessary (multiple isocenters, active motion management, mixed field types). Failure to document these circumstances may result in denial or reclassification to CPT 77407.

Document number of isocenters, presence of active motion management, or mixed modality fields to justify 77412.
If documentation is insufficient, claims may be reclassified to 77407 or denied.

Note

Not Specified / Administrative Placeholders

Not Specified / Placeholder Notes: Some inventory entries have no specific administrative or clinical rules in this section. Always check member specific benefit plans and applicable manuals for any additional requirements.

If a cited inventory entry appears blank in the policy, contact the payer medical policy unit or prior authorization vendor for clarification.
This policy is informational and does not replace the member specific benefit plan.

PurposeFacilitates selective dose escalation to gross disease while limiting dose to elective nodal volumes and OARs

APBI — definition

DefinitionAccelerated partial‑breast irradiation (APBI): radiation limited to the tumor bed delivered over a shorter timeframe as an alternative to whole‑breast irradiation in selected low‑risk patients

Typical regimen example30 Gy in five fractions (6 Gy/fraction) delivered over ~2 weeks (Florence trial) or 3,000 cGy in five once‑daily fractions on nonconsecutive days per ASTRO guidance

Selection noteAPBI via external‑beam IMRT is appropriate only for patients matching trial or guideline suitability criteria (e.g., age ≥50, Tis/T1, clear margins)

APBI — technique and typical dosing examples

Technique descriptionExternal‑beam APBI using IMRT targets the lumpectomy cavity/tumor bed and delivers higher per‑fraction doses over a short course to limit exposure of the remaining breast tissue

Representative dosing examples30 Gy in 5 once‑daily fractions (Florence trial) and 38.5 Gy in 10 twice‑daily fractions (NSABP B‑39 permitted regimens); ASTRO recommends 3,000 cGy in five once‑daily fractions as an option

Outcome summaryRandomized trials in appropriately selected patients show low ipsilateral breast tumor recurrence and reduced acute/late toxicity in some reports; patient selection per guideline is essential

PMRT — postmastectomy radiation therapy

DefinitionPostmastectomy radiation therapy (PMRT): radiation to the ipsilateral chest wall or reconstructed breast and regional nodes (axillary, supra‑/infraclavicular, internal mammary) delivered after mastectomy

IMRT roleIMRT/VMAT is recommended when 3D‑CRT cannot meet target coverage or normal tissue constraints; daily image guidance and DIBH may be used to spare heart and lungs

IndicationsTypically applied for node‑positive disease, pT4 tumors, residual nodal disease after neoadjuvant therapy, and other high‑risk features per guideline

Image‑Guided Radiation Therapy (IGRT)

DefinitionImage‑Guided Radiation Therapy (IGRT): imaging performed at the time of treatment delivery (orthogonal or volumetric such as cone‑beam CT) to verify target localization and adapt for anatomical or positional changes

Role with advanced techniquesIGRT is recommended with IMRT and SBRT to reduce margins, improve targeting accuracy, and allow safe dose escalation while protecting OARs

Documentation and verificationDaily IGRT and appropriate simulation (e.g., 4D‑CT, PET/CT) should be documented when claimed to support advanced delivery and OAR sparing

IMRT benefits

Benefit statementIMRT reduces radiation dose to adjacent normal tissues and decreases certain toxicities (e.g., xerostomia, pulmonary and GI toxicities) while maintaining tumor‑targeting capability

Evidence examplesRandomized and comparative analyses (e.g., RTOG 0617 secondary analyses, head and neck reviews) demonstrate toxicity reductions though survival benefits are not uniformly shown

Clinical implicationUse IMRT when 3D‑CRT cannot meet OAR constraints or when toxicity reduction is a primary therapeutic goal

Hippocampal‑avoidance WBRT (HA‑WBRT)

DefinitionHippocampal‑avoidance whole‑brain radiation therapy (HA‑WBRT): a WBRT technique using IMRT to spare the hippocampal region to preserve cognitive function

Concurrent medicationMemantine is used adjunctively and is recommended alongside HA‑WBRT to further mitigate cognitive decline

Eligibility and intentRecommended for patients with brain metastases who have no metastases in the hippocampal‑avoidance region and expected survival ≥4 months; typically delivered in up to 10 fractions

IGRT — imaging during delivery

DefinitionIGRT for delivery: use of imaging during treatment (orthogonal or volumetric) to verify patient setup and target localization at each fraction

PurposeEnsures accurate delivery of IMRT, accommodates anatomical changes (motion, edema, tumor shrinkage), and enables margin reduction to spare OARs

RecommendationsDaily IGRT is recommended when delivering IMRT for pelvic, thoracic, hepatic, and head and neck sites where motion or organ deformation is anticipated

BED — biologically effective dose

DefinitionBiologically effective dose (BED): a calculated dose metric used to compare different fractionation regimens and to assess dose‑escalation effects

Use in policyBED referenced to identify ablative thresholds in dose‑escalation studies (e.g., BED > 80.5 Gy associated with improved outcomes in IHC)

Clinical applicationBED guides selection of hypofractionated or ablative regimens when balancing tumor control with normal tissue tolerance

IMRT — definition and guideline endorsement

DefinitionIMRT: an advanced external‑beam technique that modulates beam intensity to conform dose to complex 3‑D tumor shapes

Guideline endorsementRecommended by major specialty societies (ASTRO, NCCN, ACR) for multiple tumor types when improved conformality or OAR sparing is needed

Clinical rationaleEnables dose escalation to targets and reduces exposure to adjacent normal structures compared with conventional techniques

IMRT/VMAT — definition and role

DefinitionIMRT/VMAT: advanced, highly conformal photon techniques (IMRT and volumetric modulated arc therapy) used to shape dose and spare OARs

RolePreferred or recommended by guidelines for many indications (e.g., pancreas, NSCLC stage III, SCLC concurrent chemoradiation) to reduce toxicity while maintaining coverage

Practical noteVMAT may offer delivery efficiency advantages while maintaining dosimetric conformity similar to IMRT

Image‑guided IMRT — definition and rationale

DefinitionImage‑guided IMRT: IMRT delivered with daily image guidance (orthogonal or volumetric) to verify localization and adapt for anatomical changes

RationaleDaily IGRT reduces setup uncertainty and allows margin reduction, improving OAR sparing and enabling safe delivery of conformal or dose‑escalated regimens

Recommended settingsAdvocated for pelvic, thoracic, hepatic, head and neck, and vulvar treatments and when using SIBs or treating areas prone to anatomical change

Image‑guided IMRT — alternate phrasing

Definition (alternate)IMRT delivered with imaging during the treatment course to accommodate anatomical changes such as edema or tumor shrinkage and to protect normal tissues within tolerance limits

Operational noteRequires documented daily setup verification and use of IGRT modalities (e.g., cone‑beam CT) when claimed

Clinical benefitEnhances reproducibility of target coverage and helps avoid geographic miss during multi‑week definitive courses

Definitive Therapy (updated definition)

Updated definitionDefinitive Therapy: radiation treatments delivered with curative intent; updated definition in policy to clarify selection depends on cancer type, stage, and multidisciplinary assessment

Revision contextPolicy revision (03/01/2026) updated the Definitive Therapy definition alongside expanded list of proven indications

Clinical implicationDefinitive intent should be explicitly documented in the medical record when used to justify IMRT for curative‑intent treatment